On 8 October 2009, orphan designation (EU/3/09/666) was granted by the European Commission to S.L.A. Pharma (UK) Ltd, United Kingdom, for eicosapentaenoic acid for the treatment of familial adenomatous polyposis.
The sponsor’s address was updated in March 2021.
The sponsorship was transferred to SLA Pharma (IRE) Limited, Ireland, in April 2021.
|Disease / condition||
Treatment of familial adenomatous polyposis (FAP)
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.